NEW YORK, NY / ACCESSWIRE / March 14, 2017 / The Biotech Sector is seeing the arrival of some new competitors, with one company continuing to overperform and another set to have its business absorbed or sold to keep its product viable. The high risk, high reward nature of low-priced stocks is being defined by several biotech stocks, especially those involved in the treatment of cancer-related drugs.
RDI Initiates Coverage:
Cerulean Pharma Inc. https://ub.rdinvesting.com/news/?ticker=CERU
Protalix Biotherapeutics Inc. https://ub.rdinvesting.com/news/?ticker=PLX
Cerulean Pharma saw its shares rise almost 64 percent, closing up 97 cents to settle at a day end close of $2.49 per share. The underlying reason for the optimism is that back on February 1st the company put out a news release that the company was investigating "potential alternatives such as the sale of the company, a merger, a business combination, a strategic investment into the company, or a sale, license or disposition of assets of the company." Now, there are apparent rumors that the company has found such an alternative, and investors are pouring in to take full advantage. The company is involved in nano-technology in the treatment of cancers. It major product is labeled as the Dynamic Tumor Targeting platform, that helps connect high concentrations of an active drug to combat tumor cells, while avoiding exposure to healthy tissue.
Access RDI's Cerulean Pharma Research Report at: https://ub.rdinvesting.com/news/?ticker=CERU
Protalix Biotherapeutics was in the pharmaceutical sector news today as its stock jumped 21 percent to close at $1.43 a share, up 25 cents from Friday’s close. It is one of the hottest biotech stocks, starting the year at $.40 a share. Some analysts see the stock with more upside potential, given its ongoing Phase 2 FDA studies for several anti-cancer drugs. Protalix is one of the few companies that create "Plantibodies" drugs, using plant cells instead of mammalian cells, making it vastly cheaper to manufacture drugs. A conference call was held on January 9 th that updated financial data and the progress of its FDA Phase 2 and Phase 3 trials. The results of the call can be presumed to be positive, giving the company the potential to knock out major players in the nano-oncology market. Its cystic fibrosis drug, AirDNase, had positive interim result on Phase 2 clinical trial on January 3rd with detailed result expected in current quarter, has a potential to make significant impact in market dominated by the competitor drug DNase. Protalix will release fourth quarter and full year financial result on March 16th.
Access RDI's Protalix Biotherapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=PLX
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.